PM360 2020 Trailblazer Awards Rare Diseases Brand Champion Matthew Rossen

Matthew Rossen, Vice President of Marketing, BridgeBio Pharma

For Matthew Rossen it is all about the patient. “At the forefront of all our hard decisions is what’s best for the patient and how do we uncover the insight to deliver against the unique needs of each individual patient,” he explains.

Those aren’t just words for Matt, he truly backs them up. Currently, he is responsible for marketing three pre-clinical products, which mostly involves disease awareness and clinical trial initiatives. One of those products is infigratinib, a potential treatment for cholangiocarcinoma, a rare bile duct cancer that affects approximately 8,000 to 10,000 individuals a year in the U.S.

Matt and his team regularly work with the Cholangiocarcinoma Foundation’s patient advisory board to glean insights about what type of information and services would be most useful to them. For instance, they learned patients taking kinase inhibitors like infigratinib can experience nail toxicity. So to ensure patients didn’t have trouble accessing their medication, they redesigned the packaging to require less effort to remove pills from the blister pack. Work on programs like this and other initiatives have led to a 2x increase in inquiries regarding their clinical trials.

Matt and the team are also exploring ways to help patients for the company’s other pre-clinical products. For achondroplasia, a bone growth disorder that affects approximately one of 20,000 newborns, they are working on an iPad program to keep kids engaged as they go through the lengthy process of getting their limbs measured. They also developed a care kit for the patients in their trials, which provides information about nutrition, side effects, and management strategies to help give them the best chance of success.


You May Also Like

PM360 2019 Innovative Service Patient Support Programs from Ashfield

Patient Support Programs Ashfield Nareda Mills, President, Patient Solutions In 2018, Ashfield Patient ...

340B Cuts Could Impact Access to Specialty Drugs

For more than 25 years, the 340B Drug Pricing Program1 has helped safety-net facilities ...

2018 Pharma Choice Multichannel Bronze Winner DiD, Propeller Communications, and Novartis

DiD and Propeller Communications Novartis Complete Patient Approach To expand the psoriasis dialogue beyond ...